BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cornberg M, Razavi HA, Alberti A, Bernasconi E, Buti M, Cooper C, Dalgard O, Dillion JF, Flisiak R, Forns X, Frankova S, Goldis A, Goulis I, Halota W, Hunyady B, Lagging M, Largen A, Makara M, Manolakopoulos S, Marcellin P, Marinho RT, Pol S, Poynard T, Puoti M, Sagalova O, Sibbel S, Simon K, Wallace C, Young K, Yurdaydin C, Zuckerman E, Negro F, Zeuzem S. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int. 2011;31 Suppl 2:30-60. [PMID: 21651702 DOI: 10.1111/j.1478-3231.2011.02539.x] [Cited by in Crossref: 272] [Cited by in F6Publishing: 255] [Article Influence: 24.7] [Reference Citation Analysis]
Number Citing Articles
1 Magiorkinis G, Sypsa V, Magiorkinis E, Paraskevis D, Katsoulidou A, Belshaw R, Fraser C, Pybus OG, Hatzakis A. Integrating phylodynamics and epidemiology to estimate transmission diversity in viral epidemics. PLoS Comput Biol. 2013;9:e1002876. [PMID: 23382662 DOI: 10.1371/journal.pcbi.1002876] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 4.6] [Reference Citation Analysis]
2 Efe C, Wahlin S, Ozaslan E, Purnak T, Muratori L, Quarneti C, Tatar G, Simsek H, Muratori P, Schiano TD. Diagnostic difficulties, therapeutic strategies, and performance of scoring systems in patients with autoimmune hepatitis and concurrent hepatitis B/C. Scand J Gastroenterol 2013;48:504-8. [PMID: 23448312 DOI: 10.3109/00365521.2013.772231] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
3 Fauvelle C, Lepiller Q, Felmlee DJ, Fofana I, Habersetzer F, Stoll-Keller F, Baumert TF, Fafi-Kremer S. Hepatitis C virus vaccines--progress and perspectives. Microb Pathog 2013;58:66-72. [PMID: 23499591 DOI: 10.1016/j.micpath.2013.02.005] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
4 Zuure FR, Bouman J, Martens M, Vanhommerig JW, Urbanus AT, Davidovich U, van Houdt R, Speksnijder AG, Weegink CJ, van den Hoek A. Screening for hepatitis B and C in first-generation Egyptian migrants living in the Netherlands. Liver Int. 2013;33:727-738. [PMID: 23448397 DOI: 10.1111/liv.12131] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
5 Yu M, Peng B, Chan K, Gong R, Yang H, Delaney W 4th, Cheng G. Robust and persistent replication of the genotype 6a hepatitis C virus replicon in cell culture. Antimicrob Agents Chemother 2014;58:2638-46. [PMID: 24550344 DOI: 10.1128/AAC.01780-13] [Cited by in Crossref: 23] [Cited by in F6Publishing: 10] [Article Influence: 2.9] [Reference Citation Analysis]
6 Manns M, Pol S, Jacobson IM, Marcellin P, Gordon SC, Peng C, Chang T, Everson GT, Heo J, Gerken G, Yoffe B, Towner WJ, Bourliere M, Metivier S, Chu C, Sievert W, Bronowicki J, Thabut D, Lee Y, Kao J, Mcphee F, Kopit J, Mendez P, Linaberry M, Hughes E, Noviello S. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. The Lancet 2014;384:1597-605. [DOI: 10.1016/s0140-6736(14)61059-x] [Cited by in Crossref: 248] [Cited by in F6Publishing: 121] [Article Influence: 31.0] [Reference Citation Analysis]
7 Wang HL, Lu X, Yang X, Xu N. Effectiveness and safety of daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: Systematic review and meta-analysis. J Gastroenterol Hepatol. 2017;32:45-52. [PMID: 27597318 DOI: 10.1111/jgh.13587] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
8 Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, Vogel W, Mendes Correa MC, Hézode C, Lázaro P. The present and future disease burden of hepatitis C virus (HCV) infection with today’s treatment paradigm. J Viral Hepat. 2014;21 Suppl 1:34-59. [PMID: 24713005 DOI: 10.1111/jvh.12248] [Cited by in Crossref: 251] [Cited by in F6Publishing: 240] [Article Influence: 31.4] [Reference Citation Analysis]
9 Wiegand SB, Heidrich B, Susser S, Rogalska-Taranta M, Petersen J, Böker KH, Grigorian N, Link R, Naumann U, John C, Lueth S, Malfertheiner P, Manns MP, Wedemeyer H, Sarrazin C, Cornberg M. Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting. PLoS One 2015;10:e0145622. [PMID: 26699619 DOI: 10.1371/journal.pone.0145622] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
10 Tozun N, Ozdogan O, Cakaloglu Y, Idilman R, Karasu Z, Akarca U, Kaymakoglu S, Ergonul O. Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect 2015;21:1020-6. [PMID: 26163105 DOI: 10.1016/j.cmi.2015.06.028] [Cited by in Crossref: 53] [Cited by in F6Publishing: 39] [Article Influence: 7.6] [Reference Citation Analysis]
11 Carrozzo M, Scally K. Oral manifestations of hepatitis C virus infection. World J Gastroenterol 2014; 20(24): 7534-7543 [PMID: 24976694 DOI: 10.3748/wjg.v20.i24.7534] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 32] [Article Influence: 4.5] [Reference Citation Analysis]
12 Aguilera A, Navarro D, Rodríguez-Frias F, Viciana I, Martínez-Sapiña AM, Rodríguez MJ, Martró E, Lozano MC, Coletta E, Cardeñoso L, Suárez A, Trigo M, Rodríguez-Granjer J, Montiel N, de la Iglesia A, Alados JC, Vegas C, Bernal S, Fernández-Cuenca F, Pena MJ, Reina G, García-Bujalance S, Echevarria MJ, Benítez L, Pérez-Castro S, Ocete D, García-Arata I, Guerrero C, Rodríguez-Iglesias M, Casas P, García F. Prevalence and distribution of hepatitis C virus genotypes in Spain during the 2000-2015 period (the GEHEP 005 study). J Viral Hepat 2017;24:725-32. [PMID: 28248445 DOI: 10.1111/jvh.12700] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
13 Buti M, Calleja JL, García-samaniego J, Serra MÁ, Crespo J, Romero M, Simón MÁ, Turnes J, Blasco AJ, Lázaro P, Robbins S, Razavi H. Elimination of hepatitis C in Spain: Adaptation of a mathematical model based on the public health strategic plan for addressing hepatitis C in the National Health System. Medicina Clínica (English Edition) 2017;148:277-82. [DOI: 10.1016/j.medcle.2017.03.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
14 Wilfret DA, Walker J, Adkison KK, Jones LA, Lou Y, Gan J, Castellino S, Moseley CL, Horton J, de Serres M. Safety, tolerability, pharmacokinetics, and antiviral activity of GSK2336805, an inhibitor of hepatitis C virus (HCV) NS5A, in healthy subjects and subjects chronically infected with HCV genotype 1. Antimicrob Agents Chemother. 2013;57:5037-5044. [PMID: 23896477 DOI: 10.1128/aac.00910-13] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
15 de Bruijn W, Ibáñez C, Frisk P, Bak Pedersen H, Alkan A, Vella Bonanno P, Brkičić LS, Bucsics A, Dedet G, Eriksen J, Fadare JO, Fürst J, Gallego G, Godói IP, Guerra Júnior AA, Gürsöz H, Jan S, Jones J, Joppi R, Kerman S, Laius O, Madzikwa N, Magnússon E, Maticic M, Markovic-Pekovic V, Massele A, Ogunleye O, O'Leary A, Piessnegger J, Sermet C, Simoens S, Tiroyakgosi C, Truter I, Thyberg M, Tomekova K, Wladysiuk M, Vandoros S, Vural EH, Zara C, Godman B. Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future. Front Pharmacol 2016;7:197. [PMID: 27516740 DOI: 10.3389/fphar.2016.00197] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
16 Reynolds CA, Davison KL, Andrews N, Patel P, Kitchen A, Brailsford SR. Dissecting the decline of hepatitis C in first-time donors in England and Wales. Vox Sang 2018;113:329-38. [PMID: 29441589 DOI: 10.1111/vox.12638] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
17 Kouyoumjian SP, Chemaitelly H, Abu-Raddad LJ. Characterizing hepatitis C virus epidemiology in Egypt: systematic reviews, meta-analyses, and meta-regressions. Sci Rep. 2018;8:1661. [PMID: 29374178 DOI: 10.1038/s41598-017-17936-4] [Cited by in Crossref: 69] [Cited by in F6Publishing: 60] [Article Influence: 17.3] [Reference Citation Analysis]
18 Salvatierra K, Fareleski S, Forcada A, López-Labrador FX. Hepatitis C virus resistance to new specifically-targeted antiviral therapy: A public health perspective. World J Virol 2013; 2(1): 6-15 [PMID: 24175225 DOI: 10.5501/wjv.v2.i1.6] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
19 Karchava M, Sharvadze L, Chkhartishvili N, Nelson K, Gochitashivli N, Gatserelia L, Dvali N, Dolmazashvili E, Dzigua L, Badridze N. IL28B favorable genotype and ultrarapid viral response as the earliest treatment predictors of a sustained viral response in a Georgian cohort infected with the hepatitis C genotype 1. Eur J Gastroenterol Hepatol. 2012;24:817-823. [PMID: 22569080 DOI: 10.1097/meg.0b013e328353fd11] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
20 Bhatia M, Gupta E. Emerging resistance to directly-acting antiviral therapy in treatment of chronic Hepatitis C infection-A brief review of literature. J Family Med Prim Care 2020;9:531-8. [PMID: 32318377 DOI: 10.4103/jfmpc.jfmpc_943_19] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
21 Bert F, Rindermann A, Abdelfattah MA, Stahmeyer JT, Rossol S. High prevalence of chronic hepatitis B and C virus infection in a population of a German metropolitan area: a prospective survey including 10 215 patients of an interdisciplinary emergency unit. Eur J Gastroenterol Hepatol 2016;28:1246-52. [PMID: 27439034 DOI: 10.1097/MEG.0000000000000702] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
22 Mahmud S, Akbarzadeh V, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Iran: Systematic review and meta-analyses. Sci Rep. 2018;8:150. [PMID: 29317673 DOI: 10.1038/s41598-017-18296-9] [Cited by in Crossref: 53] [Cited by in F6Publishing: 44] [Article Influence: 13.3] [Reference Citation Analysis]
23 Mohsen W, Rodov M, Prakoso E, Charlton B, Bowen DG, Koorey DJ, Shackel NA, McCaughan GW, Strasser SI. Patients with non-viral liver disease have a greater tumor burden and less curative treatment options when diagnosed with hepatocellular carcinoma. World J Gastroenterol 2017; 23(15): 2763-2770 [PMID: 28487614 DOI: 10.3748/wjg.v23.i15.2763] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
24 Elbasha EH, Chhatwal J, Ferrante SA, El Khoury AC, Laires PA. Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal. Appl Health Econ Health Policy 2013;11:65-78. [PMID: 23355388 DOI: 10.1007/s40258-012-0007-8] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
25 Kosack CS, Nick S, Shanks L. Diagnostic accuracy evaluation of the ImmunoFlow HCV rapid immunochromatographic test for the detection of hepatitis C antibodies. Journal of Virological Methods 2014;204:6-10. [DOI: 10.1016/j.jviromet.2014.03.012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
26 Andriulli A, Stroffolini T, Mariano A, Valvano MR, Grattagliano I, Ippolito AM, Grossi A, Brancaccio G, Coco C, Russello M, Smedile A, Petrini E, Martini S, Gaeta GB, Rizzetto M. Declining prevalence and increasing awareness of HCV infection in Italy: A population-based survey in five metropolitan areas. Eur J Intern Med. 2018;53:79-84. [PMID: 29475770 DOI: 10.1016/j.ejim.2018.02.015] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 10.3] [Reference Citation Analysis]
27 Averhoff FM, Glass N, Holtzman D. Global burden of hepatitis C: considerations for healthcare providers in the United States. Clin Infect Dis. 2012;55 Suppl 1:S10-S15. [PMID: 22715208 DOI: 10.1093/cid/cis361] [Cited by in Crossref: 185] [Cited by in F6Publishing: 182] [Article Influence: 18.5] [Reference Citation Analysis]
28 Sakr AA, Ahmed AE, Abd El-Maksoud MDE, Gamal A, El-Garem H, Ahmed OM. Interferon lambda 4 gene polymorphisms as a predicting tool of response to hepatitis C virus genotype 4 patients treated with Sofosbuvir and Ribavirin. Infect Genet Evol 2020;86:104606. [PMID: 33127459 DOI: 10.1016/j.meegid.2020.104606] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Wei L, Lok AS. Impact of new hepatitis C treatments in different regions of the world. Gastroenterology 2014; 146: 1145-50. e1-4. [PMID: 24662488 DOI: 10.1053/j.gastro.2014.03.008] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 4.8] [Reference Citation Analysis]
30 Harris M, Ward E, Gore C. Finding the undiagnosed: a qualitative exploration of hepatitis C diagnosis delay in the United Kingdom. J Viral Hepat 2016;23:479-86. [PMID: 26924296 DOI: 10.1111/jvh.12513] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 4.7] [Reference Citation Analysis]
31 Perrett S, Hams P. Raising public awareness of hepatitis B and C through a testing road show. Br J Nurs 2013;22:1308, 1310-2. [PMID: 24335868 DOI: 10.12968/bjon.2013.22.22.1308] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
32 Duffell EF, van de Laar MJ, Amato-Gauci AJ. Enhanced surveillance of hepatitis C in the EU, 2006 - 2012. J Viral Hepat 2015;22:590-5. [PMID: 25420699 DOI: 10.1111/jvh.12367] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
33 Mogalian E, German P, Kearney BP, Yang CY, Brainard D, McNally J, Moorehead L, Mathias A. Use of Multiple Probes to Assess Transporter- and Cytochrome P450-Mediated Drug-Drug Interaction Potential of the Pangenotypic HCV NS5A Inhibitor Velpatasvir. Clin Pharmacokinet. 2016;55:605-613. [PMID: 26519191 DOI: 10.1007/s40262-015-0334-7] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
34 Sundaram V, Kowdley KV. Role of ledipasvir/sofosbuvir combination for genotype 1 hepatitis C virus infection. Hepat Med 2016;8:75-80. [PMID: 27418860 DOI: 10.2147/HMER.S63125] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
35 Leventer-Roberts M, Dagan N, Berent JM, Brufman I, Hoshen M, Braun M, Balicer RD, Feldman BS. Using population-level incidence of hepatitis C virus and immigration status for data-driven screening policies: a case study in Israel. J Public Health (Oxf) 2020:fdaa215. [PMID: 33348364 DOI: 10.1093/pubmed/fdaa215] [Reference Citation Analysis]
36 Yasseen AS 3rd, Kwong JC, Feld JJ, Janjua NZ, Greenaway C, Lapointe-Shaw L, Sherman M, Mazzulli T, Kustra R, MacDonald L, Sander B, Crowcroft NS. Viral hepatitis C cascade of care: A population-level comparison of immigrant and long-term residents. Liver Int 2021;41:1775-88. [PMID: 33655665 DOI: 10.1111/liv.14840] [Reference Citation Analysis]
37 Houldsworth A, Metzner M, Hodgkinson A, Shaw S, Kaminski E, Demaine AG, Cramp ME. Haplotype analysis finds linkage disequilibrium in the IL-12 gene in patients with HCV. J Med Virol 2015;87:1207-17. [PMID: 25908236 DOI: 10.1002/jmv.24179] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
38 Dultz G, Zeuzem S. Hepatitis C Virus: A European Perspective. Gastroenterol Clin North Am. 2015;44:807-824. [PMID: 26600221 DOI: 10.1016/j.gtc.2015.07.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
39 Kretzer IF, do Livramento A, da Cunha J, Gonçalves S, Tosin I, Spada C, Treitinger A. Hepatitis C worldwide and in Brazil: silent epidemic--data on disease including incidence, transmission, prevention, and treatment. ScientificWorldJournal. 2014;2014:827849. [PMID: 25013871 DOI: 10.1155/2014/827849] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
40 Leask JD, Dillon JF. Review article: treatment as prevention - targeting people who inject drugs as a pathway towards hepatitis C eradication. Aliment Pharmacol Ther. 2016;44:145-156. [PMID: 27199103 DOI: 10.1111/apt.13673] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
41 European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2014;60:392-420. [PMID: 24331294 DOI: 10.1016/j.jhep.2013.11.003] [Cited by in Crossref: 600] [Cited by in F6Publishing: 564] [Article Influence: 66.7] [Reference Citation Analysis]
42 Alberti A, Lacoin L, Morais E, Lefevre C, Abogunrin S, Iheanacho I. Literature review of the distribution of hepatitis C virus genotypes across Europe: HCV Genotype Distribution in Europe Review. J Med Virol 2016;88:2157-69. [DOI: 10.1002/jmv.24573] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
43 Trigg A, Chan E, Kitchen H, Willgoss T, Ho KF, Pierson R, Scott J. Psychometric Validation of the Hepatitis C Symptom and Impact Questionnaire (HCV-SIQv4) in a Diverse Sample of Adults with Chronic Hepatitis C Virus Infection Treated with an Interferon-free Simeprevir-containing Regimen. J Health Econ Outcomes Res 2019;6:1-19. [PMID: 32685576 DOI: 10.36469/9675] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
44 Carvalhana SC, Leitão J, Alves AC, Bourbon M, Cortez-Pinto H. Hepatitis B and C prevalence in Portugal: disparity between the general population and high-risk groups. Eur J Gastroenterol Hepatol 2016;28:640-4. [PMID: 26866523 DOI: 10.1097/MEG.0000000000000608] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
45 Bundle N, Balasegaram S, Parry S, Ullah S, Harris RJ, Ahmad K, Foster GR, Tong CY, Orkin C. Seroprevalence and demographic factors associated with hepatitis B, hepatitis C and HIV infection from a hospital emergency department testing programme, London, United Kingdom, 2015 to 2016. Euro Surveill 2019;24. [PMID: 31290390 DOI: 10.2807/1560-7917.ES.2019.24.27.1800377] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
46 Brennan BJ, Xu ZX, Grippo JF. Effect of peginterferon alfa-2a (40KD) on cytochrome P450 isoenzyme activity. Br J Clin Pharmacol. 2013;75:497-506. [PMID: 22765278 DOI: 10.1111/j.1365-2125.2012.04373.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
47 van de Vooren K, Curto A, Garattini L. Pricing of forthcoming therapies for hepatitis C in Europe: beyond cost-effectiveness? Eur J Health Econ 2015;16:341-5. [DOI: 10.1007/s10198-014-0653-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
48 Wantuck JM, Ahmed A, Nguyen MH. Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6. Aliment Pharmacol Ther 2014;39:137-47. [DOI: 10.1111/apt.12551] [Cited by in Crossref: 61] [Cited by in F6Publishing: 62] [Article Influence: 6.8] [Reference Citation Analysis]
49 Riou J, Aït Ahmed M, Blake A, Vozlinsky S, Brichler S, Eholié S, Boëlle P, Fontanet A; the HCV epidemiology in Africa group. Hepatitis C virus seroprevalence in adults in Africa: a systematic review and meta-analysis. J Viral Hepat 2016;23:244-55. [DOI: 10.1111/jvh.12481] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 7.4] [Reference Citation Analysis]
50 Salemovic D, Pesic-Pavlovic I, Jevtovic D, Bojovic K, Ranin J, Brmbolic B, Stanojevic M. Intravenous drug use - an independent predictor for HCV genotypes 3 and 4 infection among HIV/HCV co-infected patients. Arch Med Sci. 2017;13:652-658. [PMID: 28507583 DOI: 10.5114/aoms.2017.66022] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
51 Mauger DM, Golden M, Yamane D, Williford S, Lemon SM, Martin DP, Weeks KM. Functionally conserved architecture of hepatitis C virus RNA genomes. Proc Natl Acad Sci U S A 2015;112:3692-7. [PMID: 25775547 DOI: 10.1073/pnas.1416266112] [Cited by in Crossref: 89] [Cited by in F6Publishing: 76] [Article Influence: 12.7] [Reference Citation Analysis]
52 Sundaram V, Kowdley KV. Dual daclatasvir and sofosbuvir for treatment of genotype 3 chronic hepatitis C virus infection. Expert Rev Gastroenterol Hepatol 2016;10:13-20. [PMID: 26560449 DOI: 10.1586/17474124.2016.1116937] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
53 Giudici F, Bertisch B, Negro F, Stirnimann G, Müllhaupt B, Moradpour D, Cerny A, Keiser O; Swiss Hepatitis C Cohort Study. Access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study: a person-centred approach. J Viral Hepat 2016;23:697-707. [PMID: 27006320 DOI: 10.1111/jvh.12535] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
54 Adinolfi LE, Restivo L, Guerrera B, Sellitto A, Ciervo A, Iuliano N, Rinaldi L, Santoro A, Li Vigni G, Marrone A. Chronic HCV infection is a risk factor of ischemic stroke. Atherosclerosis. 2013;231:22-26. [PMID: 24125405 DOI: 10.1016/j.atherosclerosis.2013.08.003] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 6.2] [Reference Citation Analysis]
55 Peles E, Schreiber S, Adelson M. Trends in Substance Abuse and Infectious Disease Over 20 Years in a Large Methadone Maintenance Treatment (MMT) Clinic in Israel. Substance Abuse 2014;35:226-9. [DOI: 10.1080/08897077.2014.899944] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
56 Kaucher S, Leier V, Deckert A, Holleczek B, Meisinger C, Winkler V, Becher H. Time trends of cause-specific mortality among resettlers in Germany, 1990 through 2009. Eur J Epidemiol 2017;32:289-98. [PMID: 28314982 DOI: 10.1007/s10654-017-0240-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
57 Falla AM, Hofstraat SHI, Duffell E, Hahné SJM, Tavoschi L, Veldhuijzen IK. Hepatitis B/C in the countries of the EU/EEA: a systematic review of the prevalence among at-risk groups. BMC Infect Dis 2018;18:79. [PMID: 29433454 DOI: 10.1186/s12879-018-2988-x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 11.8] [Reference Citation Analysis]
58 Luhnen M, Waffenschmidt S, Gerber-Grote A, Hanke G. Health Economic Evaluations of Sofosbuvir for Treatment of Chronic Hepatitis C: a Systematic Review. Appl Health Econ Health Policy. 2016;14:527-543. [PMID: 27329481 DOI: 10.1007/s40258-016-0253-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
59 Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013;10:553-562. [PMID: 23817321 DOI: 10.1038/nrgastro.2013.107] [Cited by in Crossref: 625] [Cited by in F6Publishing: 583] [Article Influence: 69.4] [Reference Citation Analysis]
60 Heidrich B, Wiegand SB, Buggisch P, Hinrichsen H, Link R, Möller B, Böker KH, Teuber G, Klinker H, Zehnter E, Naumann U, Busch HW, Maasoumy B, Baum U, Hardtke S, Manns MP, Wedemeyer H, Petersen J, Cornberg M; HepNet Study Group. Treatment of naïve patients with chronic hepatitis C genotypes 2 and 3 with pegylated interferon alpha and ribavirin in a real world setting: relevance for the new era of DAA. PLoS One 2014;9:e108751. [PMID: 25302676 DOI: 10.1371/journal.pone.0108751] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
61 Halota W, Flisiak R, Boroń-Kaczmarska A, Juszczyk J, Pawłowska M, Simon K, Tomasiewicz K, Małkowski P; Polish Group of HCV Experts. Recommendations for treatment of hepatitis C. Polish Group of HCV Experts - 2015. Clin Exp Hepatol 2015;1:97-104. [PMID: 28856255 DOI: 10.5114/ceh.2015.55566] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
62 Prevost TC, Presanis AM, Taylor A, Goldberg DJ, Hutchinson SJ, De Angelis D. Estimating the number of people with hepatitis C virus who have ever injected drugs and have yet to be diagnosed: an evidence synthesis approach for Scotland. Addiction 2015;110:1287-300. [PMID: 25876667 DOI: 10.1111/add.12948] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
63 Chemaitelly H, Chaabna K, Abu-Raddad LJ. The Epidemiology of Hepatitis C Virus in the Fertile Crescent: Systematic Review and Meta-Analysis. PLoS One. 2015;10:e0135281. [PMID: 26296200 DOI: 10.1371/journal.pone.0135281] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 5.9] [Reference Citation Analysis]
64 Grattagliano I, Rossi A, Marconi E, Lapi F, Cricelli C. Determinants of HCV-related complications in Italian primary care patients. Liver Int 2021. [PMID: 34268863 DOI: 10.1111/liv.15017] [Reference Citation Analysis]
65 Fosby B, Melum E, Bjøro K, Bennet W, Rasmussen A, Andersen IM, Castedal M, Olausson M, Wibeck C, Gotlieb M, Gjertsen H, Toivonen L, Foss S, Makisalo H, Nordin A, Sanengen T, Bergquist A, Larsson ME, Soderdahl G, Nowak G, Boberg KM, Isoniemi H, Keiding S, Foss A, Line PD, Friman S, Schrumpf E, Ericzon BG, Höckerstedt K, Karlsen TH. Liver transplantation in the Nordic countries - An intention to treat and post-transplant analysis from The Nordic Liver Transplant Registry 1982-2013. Scand J Gastroenterol 2015;50:797-808. [PMID: 25959101 DOI: 10.3109/00365521.2015.1036359] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 7.7] [Reference Citation Analysis]
66 Yu SC, Lin CW. Early-stage splenic diffuse large B-cell lymphoma is highly associated with hepatitis C virus infection. Kaohsiung J Med Sci. 2013;29:150-156. [PMID: 23465418 DOI: 10.1016/j.kjms.2012.08.025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
67 Pluta M, Pokorska-Śpiewak M, Aniszewska M, Kowalik-Mikołajewska B, Marczyńska M. Progress and Barriers Towards Elimination of Chronic Hepatitis C in Children. Klin Padiatr 2020. [PMID: 33339066 DOI: 10.1055/a-1304-3542] [Reference Citation Analysis]
68 Kamal SM, Ghoraba D. Epidemiology and Modes of Transmission of HCV in Developing Countries. Hepatitis C in Developing Countries. Elsevier; 2018. pp. 13-22. [DOI: 10.1016/b978-0-12-803233-6.00002-3] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
69 Chaabna K, Kouyoumjian SP, Abu-Raddad LJ. Hepatitis C Virus Epidemiology in Djibouti, Somalia, Sudan, and Yemen: Systematic Review and Meta-Analysis. PLoS One. 2016;11:e0149966. [PMID: 26900839 DOI: 10.1371/journal.pone.0149966] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
70 McGivern DR, Lemon SM. Model systems for hepatitis C research: the cup half empty? Gastroenterology 2011;141:806-9. [PMID: 21791207 DOI: 10.1053/j.gastro.2011.07.028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
71 Jack RH, Konfortion J, Coupland VH, Kocher HM, Berry DP, Allum W, Linklater KM, Møller H. Primary liver cancer incidence and survival in ethnic groups in England, 2001-2007. Cancer Epidemiol 2013;37:34-8. [PMID: 23182222 DOI: 10.1016/j.canep.2012.10.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
72 Kim DY, Kim IH, Jeong SH, Cho YK, Lee JH, Jin YJ, Lee D, Suh DJ, Han KH, Park NH, Kang HY, Jung YK, Kim YS, Kim KA, Lee YJ, Lee BS, Yim HJ, Lee HJ, Baik SK, Tak WY, Lee SJ, Chung WJ, Choi SK, Cho EY, Heo J, Kim DJ, Song BC, Kim MW, Lee J, Chae HB, Choi DH, Choi HY, Ki M. A nationwide seroepidemiology of hepatitis C virus infection in South Korea. Liver Int 2013;33:586-94. [PMID: 23356674 DOI: 10.1111/liv.12108] [Cited by in Crossref: 69] [Cited by in F6Publishing: 61] [Article Influence: 7.7] [Reference Citation Analysis]
73 Woolhouse S, Cooper E, Pickard A. "It gives me a sense of belonging": providing integrated health care and treatment to people with HCV engaged in a psycho-educational support group. Int J Drug Policy 2013;24:550-7. [PMID: 23860471 DOI: 10.1016/j.drugpo.2013.05.018] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
74 Petruzziello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol 2016; 22(34): 7824-7840 [PMID: 27678366 DOI: 10.3748/wjg.v22.i34.7824] [Cited by in CrossRef: 394] [Cited by in F6Publishing: 334] [Article Influence: 65.7] [Reference Citation Analysis]
75 Deuffic-Burban S, Deltenre P, Buti M, Stroffolini T, Parkes J, Mühlberger N, Siebert U, Moreno C, Hatzakis A, Rosenberg W. Predicted effects of treatment for HCV infection vary among European countries. Gastroenterology. 2012;143:974-985.e14. [PMID: 22863764 DOI: 10.1053/j.gastro.2012.05.054] [Cited by in Crossref: 90] [Cited by in F6Publishing: 89] [Article Influence: 9.0] [Reference Citation Analysis]
76 Polilli E, Tontodonati M, Flacco ME, Ursini T, Striani P, Di Giammartino D, Paoloni M, Vallarola L, Pressanti GL, Fragassi G, Accorsi P, Manzoli L, Parruti G. High seroprevalence of HCV in the Abruzzo Region, Italy: results on a large sample from opt-out pre-surgical screening. Infection 2016;44:85-91. [PMID: 26363567 DOI: 10.1007/s15010-015-0841-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
77 Jablonka A, Solbach P, Ringe B, Schleenvoigt BT, Dopfer C, Hampel A, Schmidt RE, Behrens GMN. Niedrige Seroprävalenz von Hepatitis C bei Flüchtlingen in Deutschland im Jahr 2015. Notfall Rettungsmed 2017;20:1-5. [DOI: 10.1007/s10049-016-0198-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
78 Yu M, Corsa AC, Xu S, Peng B, Gong R, Lee YJ, Chan K, Mo H, Delaney W 4th, Cheng G. In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons. Antiviral Res 2013;100:439-45. [PMID: 24013001 DOI: 10.1016/j.antiviral.2013.08.018] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
79 Grubyte S, Urboniene J, Nedzinskiene L, Jancoriene L. The Epidemiological Patterns of Hepatitis C in Lithuania: Changes in Surveillance from 2005 to 2018. Medicina (Kaunas) 2021;57:1120. [PMID: 34684157 DOI: 10.3390/medicina57101120] [Reference Citation Analysis]
80 Baccaglini L, Thongprasom K, Carrozzo M, Bigby M. Urban legends series: lichen planus. Oral Dis. 2013;19:128-143. [PMID: 22788669 DOI: 10.1111/j.1601-0825.2012.01953.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 4.9] [Reference Citation Analysis]
81 Rathi C, Pipaliya N, Choksi D, Parikh P, Ingle M, Sawant P. Autoimmune Hepatitis Triggered by Treatment With Pegylated Interferon α-2a and Ribavirin for Chronic Hepatitis C. ACG Case Rep J 2015;2:247-9. [PMID: 26203454 DOI: 10.14309/crj.2015.74] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
82 Büsch K, Waldenström J, Lagging M, Aleman S, Weiland O, Kövamees J, Duberg A, Söderholm J. Prevalence and comorbidities of chronic hepatitis C: a nationwide population-based register study in Sweden. Scandinavian Journal of Gastroenterology 2017;52:61-8. [DOI: 10.1080/00365521.2016.1228119] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
83 Woode ME, Abu-Zaineh M, Perriëns J, Renaud F, Wiktor S, Moatti JP. Potential market size and impact of hepatitis C treatment in low- and middle-income countries. J Viral Hepat. 2016;23:522-534. [PMID: 26924428 DOI: 10.1111/jvh.12516] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
84 Dowsett LE, Coward S, Lorenzetti DL, MacKean G, Clement F. Living with Hepatitis C Virus: A Systematic Review and Narrative Synthesis of Qualitative Literature. Can J Gastroenterol Hepatol 2017;2017:3268650. [PMID: 28529936 DOI: 10.1155/2017/3268650] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
85 Kileng H, Kjellin M, Akaberi D, Bergfors A, Duberg AS, Wesslén L, Danielsson A, Gangsøy Kristiansen M, Gutteberg T, Goll R, Lannergård A, Lennerstrand J. Personalized treatment of hepatitis C genotype 1a in Norway and Sweden 2014-2016: a study of treatment outcome in patients with or without resistance-based DAA-therapy. Scand J Gastroenterol 2018;53:1347-53. [PMID: 30394152 DOI: 10.1080/00365521.2018.1511824] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
86 Torrecillas M, Gómez-Muñoz N, Ocete MD, Cuevas PR, Madrid MD, González EO, Cardona CG, García-Deltoro M. One-step diagnosis strategy together with multidisciplinary telematics referral perform an effective approach for identifying and treating patients with active Hepatitis C infection. Ann Hepatol 2021;27:100542. [PMID: 34571265 DOI: 10.1016/j.aohep.2021.100542] [Reference Citation Analysis]
87 Puoti M, Girardi E. Chronic hepatitis C in Italy: the vanishing of the first and most consistent epidemic wave. Dig Liver Dis 2013;45:369-70. [PMID: 23567493 DOI: 10.1016/j.dld.2013.02.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
88 Tavoschi L, Mason L, Petriti U, Bunge E, Veldhuijzen I, Duffell E. Hepatitis B and C among healthcare workers and patient groups at increased risk of iatrogenic transmission in the European Union/European Economic Area. J Hosp Infect 2019;102:359-68. [PMID: 30885816 DOI: 10.1016/j.jhin.2019.03.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
89 Shabani M, Sadegh Ehdaei B, Fathi F, Dowran R. A mini-review on sofosbuvir and daclatasvir treatment in coronavirus disease 2019. New Microbes New Infect 2021;42:100895. [PMID: 33976895 DOI: 10.1016/j.nmni.2021.100895] [Reference Citation Analysis]
90 Ngui SL, Brant L, Markov PV, Tung JP, Pybus OG, Teo CG, Ramsay ME. Hepatitis C virus genotype 4 in England: diversity and demographic associations. J Med Virol 2015;87:417-23. [PMID: 25185790 DOI: 10.1002/jmv.24069] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
91 Negro F. Epidemiology of hepatitis C in Europe. Dig Liver Dis. 2014;46 Suppl 5:S158-S164. [PMID: 25453870 DOI: 10.1016/j.dld.2014.09.023] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 6.6] [Reference Citation Analysis]
92 Ciesek S, Wedemeyer H. Immunosuppression, liver injury and post-transplant HCV recurrence. J Viral Hepat. 2012;19:1-8. [PMID: 22187942 DOI: 10.1111/j.1365-2893.2011.01548.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 3.5] [Reference Citation Analysis]
93 Pfeil AM, Reich O, Guerra IM, Cure S, Negro F, Müllhaupt B, Lavanchy D, Schwenkglenks M. Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in Swiss patients with chronic hepatitis C. PLoS One 2015;10:e0126984. [PMID: 25974722 DOI: 10.1371/journal.pone.0126984] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 4.4] [Reference Citation Analysis]
94 Benedet M, Adachi D, Wong A, Wong S, Pabbaraju K, Tellier R, Tang JW. The need for a sequencing-based assay to supplement the Abbott m2000 RealTime HCV Genotype II assay: A 1 year analysis. Journal of Clinical Virology 2014;60:301-4. [DOI: 10.1016/j.jcv.2014.04.005] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
95 Hatzakis A, Chulanov V, Gadano AC, Bergin C, Ben-Ari Z, Mossong J, Schréter I, Baatarkhuu O, Acharya S, Aho I. The present and future disease burden of hepatitis C virus (HCV) infections with today’s treatment paradigm - volume 2. J Viral Hepat. 2015;22 Suppl 1:26-45. [PMID: 25560840 DOI: 10.1111/jvh.12351] [Cited by in Crossref: 93] [Cited by in F6Publishing: 82] [Article Influence: 13.3] [Reference Citation Analysis]
96 Adler H, Lambert JS. Daclatasvir for the treatment of hepatitis C virus infection. Expert Rev Gastroenterol Hepatol. 2014;8:725-738. [PMID: 24882552 DOI: 10.1586/17474124.2014.925798] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
97 Crane D, Henderson EJ, Chadwick DR. Exploring the acceptability of a 'limited patient consent procedure' for a proposed blood-borne virus screening programme: a Delphi consensus building technique. BMJ Open 2017;7:e015373. [PMID: 28554930 DOI: 10.1136/bmjopen-2016-015373] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
98 Mansberg K, Kull K, Salupere R, Prükk T, Margus B, Kariis T, Remmel T, Suurmaa K, Ott K, Jaago K, Šmidt J. A Population-Based Surveillance Study on the Epidemiology of Hepatitis C in Estonia. Medicina (Kaunas) 2018;54:E9. [PMID: 30344240 DOI: 10.3390/medicina54010009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
99 Flisiak R, Halota W, Horban A, Juszczyk J, Pawlowska M, Simon K. Prevalence and risk factors of HCV infection in Poland. Eur J Gastroenterol Hepatol. 2011;23:1213-1217. [PMID: 22002000 DOI: 10.1097/meg.0b013e32834d173c] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 3.0] [Reference Citation Analysis]
100 Elsherif O, Bannan C, Keating S, McKiernan S, Bergin C, Norris S. Outcomes from a large 10 year hepatitis C treatment programme in people who inject drugs: No effect of recent or former injecting drug use on treatment adherence or therapeutic response. PLoS One 2017;12:e0178398. [PMID: 28636638 DOI: 10.1371/journal.pone.0178398] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
101 Hofstraat SHI, Falla AM, Duffell EF, Hahné SJM, Amato-Gauci AJ, Veldhuijzen IK, Tavoschi L. Current prevalence of chronic hepatitis B and C virus infection in the general population, blood donors and pregnant women in the EU/EEA: a systematic review. Epidemiol Infect 2017;145:2873-85. [PMID: 28891457 DOI: 10.1017/S0950268817001947] [Cited by in Crossref: 50] [Cited by in F6Publishing: 32] [Article Influence: 10.0] [Reference Citation Analysis]
102 Sacks-Davis R, Daniel M, Roy É, Kestens Y, Zang G, Ramos Y, Hellard M, Jutras Aswad D, Bruneau J. The role of living context in prescription opioid injection and the associated risk of hepatitis C infection. Addiction 2016;111:1985-96. [PMID: 27238912 DOI: 10.1111/add.13470] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
103 Saeed M, Scheel TK, Gottwein JM, Marukian S, Dustin LB, Bukh J, Rice CM. Efficient replication of genotype 3a and 4a hepatitis C virus replicons in human hepatoma cells. Antimicrob Agents Chemother 2012;56:5365-73. [PMID: 22869572 DOI: 10.1128/AAC.01256-12] [Cited by in Crossref: 99] [Cited by in F6Publishing: 58] [Article Influence: 9.9] [Reference Citation Analysis]
104 Bartenschlager R, Lohmann V, Penin F. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat Rev Microbiol. 2013;11:482-496. [PMID: 23748342 DOI: 10.1038/nrmicro3046] [Cited by in Crossref: 262] [Cited by in F6Publishing: 239] [Article Influence: 29.1] [Reference Citation Analysis]
105 Afaghi P, Lapolla MA, Ghandi K. Percutaneous microwave ablation applications for liver tumors: recommendations for COVID-19 patients. Heliyon 2021;7:e06454. [PMID: 33748501 DOI: 10.1016/j.heliyon.2021.e06454] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
106 Greenaway C, Thu Ma A, Kloda LA, Klein M, Cnossen S, Schwarzer G, Shrier I. The Seroprevalence of Hepatitis C Antibodies in Immigrants and Refugees from Intermediate and High Endemic Countries: A Systematic Review and Meta-Analysis. PLoS One. 2015;10:e0141715. [PMID: 26558905 DOI: 10.1371/journal.pone.0141715] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 6.7] [Reference Citation Analysis]
107 Saraswat V, Norris S, de Knegt RJ, Sanchez Avila JF, Sonderup M, Zuckerman E, Arkkila P, Stedman C, Acharya S, Aho I. Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 2. J Viral Hepat. 2015;22 Suppl 1:6-25. [PMID: 25560839 DOI: 10.1111/jvh.12350] [Cited by in Crossref: 81] [Cited by in F6Publishing: 70] [Article Influence: 11.6] [Reference Citation Analysis]
108 Cheng W, Yang Y, Zhou Y, Xiao P, Shi Y, Gao J, Chen Y, Liang S, Yihuo W, Song X, Jiang Q. Prevalence of hepatitis C virus infection and its correlates in a rural area of southwestern China: a community-based cross-sectional study. BMJ Open 2017;7:e015717. [PMID: 28801405 DOI: 10.1136/bmjopen-2016-015717] [Reference Citation Analysis]
109 McLeod A, Cullen BL, Hutchinson SJ, Roy KM, Dillon JF, Stewart EA, Goldberg DJ. Limited impact of awareness-raising campaigns on hepatitis C testing practices among general practitioners. J Viral Hepat 2017;24:944-54. [PMID: 28502088 DOI: 10.1111/jvh.12724] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
110 Chaabna K, Kouyoumjian SP, Abu-Raddad LJ. Hepatitis C Virus Epidemiology in Djibouti, Somalia, Sudan, and Yemen: Systematic Review and Meta-Analysis. PLoS One. 2016;11:e0149966. [PMID: 26900839 DOI: 10.1371/journal.pone.0149966].] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
111 Maasoumy B, Port K, Markova AA, Serrano BC, Rogalska-Taranta M, Sollik L, Mix C, Kirschner J, Manns MP, Wedemeyer H. Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting. PLoS One. 2013;8:e55285. [PMID: 23383319 DOI: 10.1371/journal.pone.0055285] [Cited by in Crossref: 77] [Cited by in F6Publishing: 74] [Article Influence: 8.6] [Reference Citation Analysis]
112 Mangia A, Mottola L. What’s new in HCV genotype 2 treatment. Liver Int. 2012;32 Suppl 1:135-140. [PMID: 22212584 DOI: 10.1111/j.1478-3231.2011.02710.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
113 Ruta S, Cernescu C. Injecting drug use: A vector for the introduction of new hepatitis C virus genotypes. World J Gastroenterol 2015; 21(38): 10811-10823 [PMID: 26478672 DOI: 10.3748/wjg.v21.i38.10811] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
114 Wáng YXJ, Li YT, Chevallier O, Huang H, Leung JCS, Chen W, Lu PX. Dependence of intravoxel incoherent motion diffusion MR threshold b-value selection for separating perfusion and diffusion compartments and liver fibrosis diagnostic performance. Acta Radiol 2019;60:3-12. [PMID: 29742916 DOI: 10.1177/0284185118774913] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
115 Ippolito AM, Iacobellis A, Milella M, Conti F, Messina V, Valvano MR, Niro GA, Morisco F, Barone M, Termite AP, Brancaccio G, Andriulli A. Hepatitis C Virus Clearance in Older Adults. J Am Geriatr Soc 2018;66:85-91. [PMID: 29135030 DOI: 10.1111/jgs.15140] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
116 Matza LS, Sapra SJ, Dillon JF, Kalsekar A, Davies EW, Devine MK, Jordan JB, Landrian AS, Feeny DH. Health state utilities associated with attributes of treatments for hepatitis C. Eur J Health Econ 2015;16:1005-18. [PMID: 25481796 DOI: 10.1007/s10198-014-0649-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
117 Brazzelli V, Carugno A, Alborghetti A, Cananzi R, Sangiovanni L, Barbarini G, De Silvestri A, Borroni RG. Hepatitis C infection in Italian psoriatic patients: prevalence and correlation with patient age and psoriasis severity. J Eur Acad Dermatol Venereol 2012;26:1581-2. [PMID: 22142565 DOI: 10.1111/j.1468-3083.2011.04360.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
118 Suthar AB, Harries AD. A public health approach to hepatitis C control in low- and middle-income countries. PLoS Med. 2015;12:e1001795. [PMID: 25757228 DOI: 10.1371/journal.pmed.1001795] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
119 Giannini EG, Marenco S, Fazio V, Pieri G, Savarino V, Picciotto A. Peripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy. Liver Int. 2012;32:1113-1119. [PMID: 22471814 DOI: 10.1111/j.1478-3231.2012.02798.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
120 daCosta DiBonaventura M, Yuan Y, Wagner JS, L'Italien GJ, Lescrauwaet B, Langley P. The burden of viral hepatitis C in Europe: a propensity analysis of patient outcomes. Eur J Gastroenterol Hepatol 2012;24:869-77. [PMID: 22617367 DOI: 10.1097/MEG.0b013e3283551dee] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
121 Peng B, Yu M, Xu S, Lee YJ, Tian Y, Yang H, Chan K, Mo H, McHutchison J, Delaney W 4th, Cheng G. Development of robust hepatitis C virus genotype 4 subgenomic replicons. Gastroenterology 2013;144:59-61.e6. [PMID: 23000598 DOI: 10.1053/j.gastro.2012.09.033] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
122 Buti M, Calleja JL, García-Samaniego J, Serra MÁ, Crespo J, Romero M, Simón MÁ, Turnes J, Blasco AJ, Lázaro P, Robbins S, Razavi H; en representación del Grupo para el Estudio y Modelización Epidemiológica de la Hepatitis C en España (GEMEHCE). Elimination of hepatitis C in Spain: Adaptation of a mathematical model based on the public health strategic plan for addressing hepatitis C in the National Health System. Med Clin (Barc) 2017;148:277-82. [PMID: 28159349 DOI: 10.1016/j.medcli.2016.12.018] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 3.4] [Reference Citation Analysis]
123 Houri I, Horowitz N, Katchman H, Weksler Y, Miller O, Deutsch L, Shibolet O. Emergency department targeted screening for hepatitis C does not improve linkage to care. World J Gastroenterol 2020; 26(32): 4878-4888 [PMID: 32921964 DOI: 10.3748/wjg.v26.i32.4878] [Reference Citation Analysis]
124 Vukotic R, Gamal N, Andreone P. Prospective, observational real-life study on eligibility for and outcomes of antiviral treatment with peginterferon α plus ribavirin in chronic hepatitis C. Dig Liver Dis 2015;47:151-6. [PMID: 25483909 DOI: 10.1016/j.dld.2014.11.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
125 Makuza JD, Liu CY, Ntihabose CK, Dushimiyimana D, Umuraza S, Nisingizwe MP, Umutesi J, Serumondo J, Mugeni SD, Semakula M, Gupta N, Hellard M, Nsanzimana S. Risk factors for viral hepatitis C infection in Rwanda: results from a nationwide screening program. BMC Infect Dis 2019;19:688. [PMID: 31382901 DOI: 10.1186/s12879-019-4322-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
126 Liakina V, Hamid S, Tanaka J, Olafsson S, Sharara AI, Alavian SM, Gheorghe L, El Hassan ES, Abaalkhail F, Abbas Z. Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 3. J Viral Hepat. 2015;22 Suppl 4:4-20. [PMID: 26513445 DOI: 10.1111/jvh.12475] [Cited by in Crossref: 63] [Cited by in F6Publishing: 56] [Article Influence: 10.5] [Reference Citation Analysis]
127 Al Kanaani Z, Mahmud S, Kouyoumjian SP, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Pakistan: systematic review and meta-analyses. R Soc Open Sci. 2018;5:180257. [PMID: 29765698 DOI: 10.1098/rsos.180257] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 9.3] [Reference Citation Analysis]
128 Li Y, Zhao L, Geng N, Zhu W, Liu H, Bai H. Prevalence and characteristics of hepatitis C virus infection in Shenyang City, Northeast China, and prediction of HCV RNA positivity according to serum anti-HCV level: retrospective review of hospital data. Virol J 2020;17:36. [PMID: 32178702 DOI: 10.1186/s12985-020-01316-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
129 Mangia A, Susser S, Piazzolla V, Agostinacchio E, De Stefano G, Palmieri V, Spinzi G, Carraturo I, Potenza D, Losappio R, Arleo A, Miscio M, Santoro R, Sarrazin C, Copetti M. Sofosbuvir and ribavirin for genotype 2 HCV infected patients with cirrhosis: A real life experience. J Hepatol 2017;66:711-7. [PMID: 27965158 DOI: 10.1016/j.jhep.2016.12.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
130 Muñoz-espinosa LE, Trujillo-trujillo ME, Martínez-macías RF, Panduro A, Rivas-estilla AM, Fierro NA, Silvera-linares AL, Torres-valadez R, Cordero-pérez P, González-aldaco K, Chen-lópez CY, José-abrego A, Zuñiga-noriega JR, Gutiérrez-ruiz MC, Roman S. Increase of drug use and genotype 3 in HCV-infected patients from Central West and Northeast Mexico. Annals of Hepatology 2015;14:642-51. [DOI: 10.1016/s1665-2681(19)30758-6] [Cited by in Crossref: 10] [Article Influence: 1.4] [Reference Citation Analysis]
131 Crespo J, Cabezas J, Sacristán B, Olcoz JL, Pérez R, De la Vega J, García R, García-pajares F, Sáez-royuela F, González JM, Jiménez F, Rodríguez S, Cuadrado A, López-arias MJ, García I, Milla A, García-riesco E, Muñoz M, Sánchez-antolín G, Jorquera F. Barriers to HCV treatment in the era of triple therapy: a prospective multi-centred study in clinical practice. Liver Int 2015;35:401-8. [DOI: 10.1111/liv.12536] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
132 Rogalska-Taranta M, Markova AA, Taranta A, Lunemann S, Schlaphoff V, Flisiak R, Manns MP, Cornberg M, Kraft AR, Wedemeyer H. Altered effector functions of NK cells in chronic hepatitis C are associated with IFNL3 polymorphism. J Leukoc Biol 2015;98:283-94. [PMID: 26034208 DOI: 10.1189/jlb.4A1014-520R] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
133 Howes N, Lattimore S, Irving WL, Thomson BJ. Clinical Care Pathways for Patients With Hepatitis C: Reducing Critical Barriers to Effective Treatment. Open Forum Infect Dis. 2016;3:ofv218. [PMID: 26900576 DOI: 10.1093/ofid/ofv218] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
134 Kutala BK, Mouri F, Castelnau C, Bouton V, Giuily N, Boyer N, Asselah T, Marcellin P. Efficacy and safety of sofosbuvir-based therapies in patients with advanced liver disease in a real-life cohort. Hepat Med 2017;9:67-73. [PMID: 29296102 DOI: 10.2147/HMER.S149578] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
135 Chlibek R, Smetana J, Sosovickova R, Gal P, Dite P, Stepanova V, Pliskova L, Plisek S. Prevalence of hepatitis C virus in adult population in the Czech Republic - time for birth cohort screening. PLoS One 2017;12:e0175525. [PMID: 28406947 DOI: 10.1371/journal.pone.0175525] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
136 Sadler MD, Lee SS. Hepatitis C virus infection in Canada's First Nations people: a growing problem. Can J Gastroenterol 2013;27:335. [PMID: 23781515 DOI: 10.1155/2013/641585] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
137 Flisiak R, Jaroszewicz J, Parfieniuk-Kowerda A. Emerging treatments for hepatitis C. Expert Opin Emerg Drugs 2013;18:461-75. [PMID: 24102413 DOI: 10.1517/14728214.2013.847089] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.7] [Reference Citation Analysis]
138 Nam JY, Jang ES, Kim YS, Lee YJ, Kim IH, Cho SB, Lee HC, Bae SH, Ki M, Choi HY, Lee EY, Jeong SH. Epidemiological and Clinical Characteristics of Hepatitis C Virus Infection in South Korea from 2007 to 2017: A Prospective Multicenter Cohort Study. Gut Liver 2020;14:207-17. [PMID: 31158950 DOI: 10.5009/gnl19005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
139 Avisar N, Heller Y, Weil C, Ben-Baruch A, Potesman-Yona S, Oren R, Chodick G, Shalev V, Ash N. Multi-disciplinary patient-centered model for the expedited provision of costly therapies in community settings: the case of new medication for hepatitis C. Isr J Health Policy Res 2017;6:46. [PMID: 28954630 DOI: 10.1186/s13584-017-0172-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
140 Garbuglia AR, Monachetti A, Galli C, Sabatini R, Ferreri ML, Capobianchi MR, Bagnarelli P. HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes. BMC Infect Dis. 2014;14:222. [PMID: 24758157 DOI: 10.1186/1471-2334-14-222] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
141 Garriga C, Manzanares-Laya S, García de Olalla P, Gorrindo P, Lens S, Solà R, Martínez-Rebollar M, Laguno M, Navarro J, Torras X, Gurguí M, Barberá MJ, Quer J, Masdeu E, Simón P, Ros M, de Andrés A, Caylà JA. Evolution of acute hepatitis C virus infection in a large European city: Trends and new patterns. PLoS One 2017;12:e0187893. [PMID: 29135988 DOI: 10.1371/journal.pone.0187893] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
142 Michaeli N, Litvin A, Davidovitch N. Hepatitis C in Israeli prisons: status report. Harm Reduct J 2020;17:79. [PMID: 33076926 DOI: 10.1186/s12954-020-00430-y] [Reference Citation Analysis]
143 Tran L, Nhu Y M, Le Ba Nghia T, Hendam A, Vuong NL, Alzalal E, Sayed AM, Hussain MM, Sharma A, Tieu T, Mathenge PG, Hirayama K, Alexander N, Huy NT. Frequent inappropriate use of unweighted summary statistics in systematic reviews of pathogen genotypes or genogroups. J Clin Epidemiol 2020;119:26-35. [PMID: 31740320 DOI: 10.1016/j.jclinepi.2019.11.009] [Reference Citation Analysis]
144 Dibonaventura MD, Yuan Y, Lescrauwaet B, L'italien G, Liu GG, Kamae I, Mauskopf JA. Multicountry burden of chronic hepatitis C viral infection among those aware of their diagnosis: a patient survey. PLoS One. 2014;9:e86070. [PMID: 24465875 DOI: 10.1371/journal.pone.0086070] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
145 Manuylov VA, Chub EV, Kichatova VS, Soboleva NV, Isaeva OV, Zamyatnin AA Jr, Netesov SV. Hepatitis C virus subtype 3a was introduced in the USSR in the early 1980s. J Gen Virol 2017;98:2079-87. [PMID: 28742003 DOI: 10.1099/jgv.0.000878] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
146 Marciano S, Gadano AC. How to optimize current treatment of genotype 2 hepatitis C virus infection. Liver Int 2014;34:13-7. [DOI: 10.1111/liv.12399] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
147 Helsper CW, Janssen MP, van Essen GA, Croes EA, van der Veen C, de Wit AG, de Wit NJ. Effectiveness and cost-effectiveness of nationwide campaigns for awareness and case finding of hepatitis C targeted at people who inject drugs and the general population in the Netherlands. Int J Drug Policy 2017;47:117-25. [PMID: 28826994 DOI: 10.1016/j.drugpo.2017.07.022] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
148 Jafri SM, Gordon SC. The safety of daclatasvir for the treatment of hepatitis C. Expert Opin Drug Saf 2015;14:1787-97. [PMID: 26571362 DOI: 10.1517/14740338.2015.1100603] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
149 Papatheodoridis G, Hatzakis A. Public health issues of hepatitis C virus infection. Best Practice & Research Clinical Gastroenterology 2012;26:371-80. [DOI: 10.1016/j.bpg.2012.09.012] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
150 Monti G, Saccardo F, Castelnovo L, Novati P, Sollima S, Riva A, Sarzi-Puttini P, Quartuccio L, De Vita S, Galli M. Prevalence of mixed cryoglobulinaemia syndrome and circulating cryoglobulins in a population-based survey: the Origgio study. Autoimmun Rev. 2014;13:609-614. [PMID: 24418294 DOI: 10.1016/j.autrev.2013.11.005] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 2.9] [Reference Citation Analysis]
151 Flisiak R, Pogorzelska J, Berak H, Horban A, Orłowska I, Simon K, Tuchendler E, Madej G, Piekarska A, Jabłkowski M, Deroń Z, Mazur W, Kaczmarczyk M, Janczewska E, Pisula A, Smykał J, Nowak K, Matukiewicz M, Halota W, Wernik J, Sikorska K, Mozer-Lisewska I, Rozpłochowski B, Garlicki A, Tomasiewicz K, Krzowska-Firych J, Baka-Ćwierz B, Kryczka W, Zarębska-Michaluk D, Olszok I, Boroń-Kaczmarska A, Sobala-Szczygieł B, Szlauer B, Korcz-Ondrzejek B, Sieklucki J, Pleśniak R, Ruszała A, Postawa-Kłosińska B, Citko J, Lachowicz-Wawrzyniak A, Musialik J, Jezierska E, Dobracki W, Dobracka B, Hałubiec J, Krygier R, Strokowska A, Chomczyk W, Witczak-Malinowska K. Prevalence of HCV genotypes in Poland - the EpiTer study. Clin Exp Hepatol 2016;2:144-8. [PMID: 28856279 DOI: 10.5114/ceh.2016.63871] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
152 Schmidt AJ, Falcato L, Zahno B, Burri A, Regenass S, Müllhaupt B, Bruggmann P. Prevalence of hepatitis C in a Swiss sample of men who have sex with men: whom to screen for HCV infection? BMC Public Health 2014;14:3. [PMID: 24393532 DOI: 10.1186/1471-2458-14-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
153 Cannalire R, Barreca ML, Manfroni G, Cecchetti V. A Journey around the Medicinal Chemistry of Hepatitis C Virus Inhibitors Targeting NS4B: From Target to Preclinical Drug Candidates. J Med Chem 2016;59:16-41. [PMID: 26241789 DOI: 10.1021/acs.jmedchem.5b00825] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
154 Mangia A, Arleo A, Copetti M, Miscio M, Piazzolla V, Santoro R, Squillante MM. The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin. Liver Int 2016;36:971-6. [PMID: 26786792 DOI: 10.1111/liv.13069] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
155 Marinho RT, Costa A, Pires T, Raposo H, Vasconcelos C, Polónia C, Borges J, Soares M, Vilar G, Nogueira AM; LIGUE-C Investigators. A multidimensional education program at substance dependence treatment centers improves patient knowledge and hepatitis C care. BMC Infect Dis 2016;16:565. [PMID: 27733137 DOI: 10.1186/s12879-016-1883-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
156 Niu Z, Zhang P, Tong Y. Age and gender distribution of Hepatitis C virus prevalence and genotypes of individuals of physical examination in WuHan, Central China. Springerplus 2016;5:1557. [PMID: 27652130 DOI: 10.1186/s40064-016-3224-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
157 Walewska-Zielecka B, Religioni U, Juszczyk G, Czerw A, Wawrzyniak Z, Soszyński P. Diagnosis of hepatitis C virus infection in pregnant women in the healthcare system in Poland: Is it worth the effort? Medicine (Baltimore) 2016;95:e4331. [PMID: 27472714 DOI: 10.1097/MD.0000000000004331] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
158 Zeuzem S, Hézode C, Bronowicki JP, Loustaud-Ratti V, Gea F, Buti M, Olveira A, Banyai T, Al-Assi MT, Petersen J, Thabut D, Gadano A, Pruitt R, Makara M, Bourlière M, Pol S, Beumont-Mauviel M, Ouwerkerk-Mahadevan S, Picchio G, Bifano M, McPhee F, Boparai N, Cheung K, Hughes EA, Noviello S; LEAGUE-1 Study Team. Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection. J Hepatol 2016;64:292-300. [PMID: 26453968 DOI: 10.1016/j.jhep.2015.09.024] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
159 Schröeder SE, Pedrana A, Scott N, Wilson D, Kuschel C, Aufegger L, Atun R, Baptista-Leite R, Butsashvili M, El-Sayed M, Getahun A, Hamid S, Hammad R, 't Hoen E, Hutchinson SJ, Lazarus JV, Lesi O, Li W, Binti Mohamed R, Olafsson S, Peck R, Sohn AH, Sonderup M, Spearman CW, Swan T, Thursz M, Walker T, Hellard M, Howell J. Innovative strategies for the elimination of viral hepatitis at a national level: A country case series. Liver Int 2019;39:1818-36. [PMID: 31433902 DOI: 10.1111/liv.14222] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
160 Gountas I, Sypsa V, Blach S, Razavi H, Hatzakis A. HCV elimination among people who inject drugs. Modelling pre- and post-WHO elimination era. PLoS One. 2018;13:e0202109. [PMID: 30114207 DOI: 10.1371/journal.pone.0202109] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
161 Dalgard O, Weiland O, Noraberg G, Karlsen L, Heggelund L, Färkkilâ M, Balslev U, Belard E, Øvrehus A, Skalshøi Kjær M, Krarup H, Thorup Røge B, Hallager S, Madsen LG, Lund Laursen A, Lagging M, Weis N. Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study. PLoS One 2017;12:e0179764. [PMID: 28704381 DOI: 10.1371/journal.pone.0179764] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
162 Falla AM, Ahmad AA, Duffell E, Noori T, Veldhuijzen IK. Estimating the scale of chronic hepatitis C virus infection in the EU/EEA: a focus on migrants from anti-HCV endemic countries. BMC Infect Dis 2018;18:42. [PMID: 29338702 DOI: 10.1186/s12879-017-2908-5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
163 Pawlotsky JM, Flisiak R, Sarin SK, Rasenack J, Piratvisuth T, Chuang WL, Peng CY, Foster GR, Shah S, Wedemeyer H. Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection. Hepatology. 2015;62:1013-1023. [PMID: 26118427 DOI: 10.1002/hep.27960] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 4.9] [Reference Citation Analysis]
164 Höner zu Siederdissen C, Manns MP, Cornberg M. [Which treatment options are validated for chronic viral hepatitis?]. Internist (Berl) 2013;54:1427-8, 1430-3. [PMID: 24258199 DOI: 10.1007/s00108-013-3319-3] [Reference Citation Analysis]
165 Mangia A, Mottola L, Piazzolla V. Update on the treatment of patients with non-genotype 1 hepatitis C virus infection. Clin Infect Dis 2013;56:1294-300. [PMID: 23271787 DOI: 10.1093/cid/cis1195] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
166 Bruggmann P, Berg T, Øvrehus AL, Moreno C, Brandão Mello CE, Roudot-Thoraval F, Marinho RT, Sherman M, Ryder SD, Sperl J, Akarca U, Balık I, Bihl F, Bilodeau M, Blasco AJ, Buti M, Calinas F, Calleja JL, Cheinquer H, Christensen PB, Clausen M, Coelho HS, Cornberg M, Cramp ME, Dore GJ, Doss W, Duberg AS, El-Sayed MH, Ergör G, Esmat G, Estes C, Falconer K, Félix J, Ferraz ML, Ferreira PR, Frankova S, García-Samaniego J, Gerstoft J, Giria JA, Gonçales FL Jr, Gower E, Gschwantler M, Guimarães Pessôa M, Hézode C, Hofer H, Husa P, Idilman R, Kåberg M, Kaita KD, Kautz A, Kaymakoglu S, Krajden M, Krarup H, Laleman W, Lavanchy D, Lázaro P, Marotta P, Mauss S, Mendes Correa MC, Müllhaupt B, Myers RP, Negro F, Nemecek V, Örmeci N, Parkes J, Peltekian KM, Ramji A, Razavi H, Reis N, Roberts SK, Rosenberg WM, Sarmento-Castro R, Sarrazin C, Semela D, Shiha GE, Sievert W, Stärkel P, Stauber RE, Thompson AJ, Urbanek P, van Thiel I, Van Vlierberghe H, Vandijck D, Vogel W, Waked I, Wedemeyer H, Weis N, Wiegand J, Yosry A, Zekry A, Van Damme P, Aleman S, Hindman SJ. Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat 2014;21 Suppl 1:5-33. [PMID: 24713004 DOI: 10.1111/jvh.12247] [Cited by in Crossref: 175] [Cited by in F6Publishing: 157] [Article Influence: 21.9] [Reference Citation Analysis]
167 Vilibic-Cavlek T, Kucinar J, Kaic B, Vilibic M, Pandak N, Barbic L, Stevanovic V, Vranes J. Epidemiology of hepatitis C in Croatia in the European context. World J Gastroenterol 2015; 21(32): 9476-9493 [PMID: 26327756 DOI: 10.3748/wjg.v21.i32.9476] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
168 Jaroszewicz J, Flisiak R, Dusheiko G. A pill for HCV - myth or foreseeable future? Liver Int 2014;34:6-11. [DOI: 10.1111/liv.12294] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
169 Frei P, Leucht AK, Held U, Kofmehl R, Manser CN, Schmitt J, Mertens J, Rau M, Baur K, Gerlach T. Elderly age is not a negative predictive factor for virological response to therapy with pegylated interferon-α and ribavirin in chronic hepatitis C virus patients. Liver Int. 2014;34:551-557. [PMID: 24034338 DOI: 10.1111/liv.12279] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
170 Weil C, Nwankwo C, Friedman M, Kenet G, Chodick G, Shalev V. Epidemiology of hepatitis C virus infection in a large Israeli health maintenance organization: Epidemiology of Hepatitis C in a large Israeli HMO. J Med Virol 2016;88:1044-50. [DOI: 10.1002/jmv.24426] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
171 Anwar WA, El Gaafary M, Girgis SA, Rafik M, Hussein WM, Sos D, Mossad IM, Fontanet A, Temime L. Hepatitis C virus infection and risk factors among patients and health-care workers of Ain Shams University hospitals, Cairo, Egypt. PLoS One 2021;16:e0246836. [PMID: 33556152 DOI: 10.1371/journal.pone.0246836] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
172 Shire NJ, Sherman KE. Epidemiology of Hepatitis C Virus: A Battle on New Frontiers. Gastroenterol Clin North Am 2015;44:699-716. [PMID: 26600215 DOI: 10.1016/j.gtc.2015.07.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
173 Lagging M, Duberg AS, Wejstål R, Weiland O, Lindh M, Aleman S, Josephson F; Swedish Consensus Group. Treatment of hepatitis C virus infection in adults and children: updated Swedish consensus recommendations. Scand J Infect Dis 2012;44:502-21. [PMID: 22506634 DOI: 10.3109/00365548.2012.669045] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
174 Igarashi A, Tang W, Guerra I, Marié L, Cure S, Lopresti M. Cost-utility analysis of ledipasvir/sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan. Curr Med Res Opin 2017;33:11-21. [PMID: 27609424 DOI: 10.1080/03007995.2016.1222513] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
175 Grandal M, Pernas B, Mariño A, Álvarez H, Tabernilla A, Castro-Iglesias Á, Mena Á, Delgado M, Pértega S, Poveda E. Characterization of chronic HCV infection in Northwest Spain: Impact of the treatment strategic plan of the Spanish National Health Service on HCV cure. J Med Virol 2017;89:1304-8. [PMID: 28079256 DOI: 10.1002/jmv.24766] [Reference Citation Analysis]
176 Marciano S, Borzi SM, Dirchwolf M, Ridruejo E, Mendizabal M, Bessone F, Sirotinsky ME, Giunta DH, Trinks J, Olivera PA, Galdame OA, Silva MO, Fainboim HA, Gadano AC. Pre-treatment prediction of response to peginterferon plus ribavirin in chronic hepatitis C genotype 3. World J Hepatol 2015; 7(4): 703-709 [PMID: 25866607 DOI: 10.4254/wjh.v7.i4.703] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
177 Zavaglia C, Silini E, Mangia A, Airoldi A, Piazzolla V, Vangeli M, Stigliano R, Foschi A, Mazzarelli C, Tinelli C. Prognostic factors of hepatic decompensation and hepatocellular carcinoma in patients with transfusion-acquired HCV infection. Liver Int 2014;34:e308-16. [PMID: 24529078 DOI: 10.1111/liv.12502] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
178 Bert F, Stahmeyer JT, Parpalea AL, Rossol S. Non-Invasive Reliable Methods to Objectify the Positive Influence of Hepatitis C Virus Treatment on Liver Stiffness. Gastroenterology Res 2021;14:31-40. [PMID: 33737997 DOI: 10.14740/gr1347] [Reference Citation Analysis]
179 Domagalski K, Pawlowska M, Tretyn A, Halota W, Tyczyno M, Kozielewicz D, Dybowska D. Association of IL28B Polymorphisms With the Response to Peginterferon Plus Ribavirin Combined Therapy in Polish Patients Infected With HCV Genotype 1 and 4. Hepat Mon. 2013;13:e13678. [PMID: 24348648 DOI: 10.5812/hepatmon.13678] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
180 Brennan BJ, Morcos PN, Wang K, Blotner SD, Morrison R, Hagedorn CH, Marbury TC, Sulkowski M, Grippo JF. The pharmacokinetics of peginterferon alfa-2a and ribavirin in African American, Hispanic and Caucasian patients with chronic hepatitis C. Aliment Pharmacol Ther 2012;35:1209-20. [DOI: 10.1111/j.1365-2036.2012.05079.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
181 Cooper CL, Read D, Vachon ML, Conway B, Wong A, Ramji A, Borgia S, Tam E, Barrett L, Smyth D, Feld JJ, Lee S; CANUHC Cohort. Hepatitis C virus infection characteristics and treatment outcomes in Canadian immigrants. BMC Public Health 2020;20:1345. [PMID: 32883249 DOI: 10.1186/s12889-020-09464-0] [Reference Citation Analysis]
182 Greenaway C, Makarenko I, Tanveer F, Janjua NZ. Addressing hepatitis C in the foreign-born population: A key to hepatitis C virus elimination in Canada. CanLivJ 2018;1:34-50. [DOI: 10.3138/canlivj.1.2.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
183 Ansaldi F, Orsi A, Sticchi L, Bruzzone B, Icardi G. Hepatitis C virus in the new era: Perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. World J Gastroenterol 2014; 20(29): 9633-9652 [PMID: 25110404 DOI: 10.3748/wjg.v20.i29.9633] [Cited by in CrossRef: 96] [Cited by in F6Publishing: 81] [Article Influence: 12.0] [Reference Citation Analysis]
184 Kartashev V, Döring M, Nieto L, Coletta E, Kaiser R, Sierra S, Guerrero A, Stoiber H, Paar C, Vandamme A, Nevens F, Ranst MV, Cuypers L, Braun P, Ehret R, Obermeier M, Schneeweiss S, Scholten S, Römer K, Isernhagen K, Qurashi N, Heger E, Knops E, Neumann-fraune M, Timm J, Walker A, Lübke N, Wedemeyer H, Wiesch JSZ, Lütgehetmann M, Polywka S, Däumer M, Hoffmann D, Protzer U, Marascio N, Foca A, Liberto M, Barreca G, Galati L, Torti C, Pisani V, Perno C, Ceccherini-silberstein F, Cento V, Ciotti M, Zazzi M, Rossetti B, Luca A, Caudai C, Mor O, Devaux C, Staub T, Araujo F, Gomes P, Cabanas J, Markin N, Khomenko I, Govorukhina M, Lugovskaya G, Dontsov D, Mas A, Martró E, Saludes V, Rodríguez-frías F, García F, Casas P, Iglesia ADL, Alados J, Pena-lópez M, Rodríguez M, Galán J, Suárez A, Cardeñoso L, Guerrero M, Vegas-dominguez C, Blas-espada J, García R, García-bujalance S, Benítez-gutiérrez L, Mendoza CD, Montiel N, Santos J, Viciana I, Delgado A, Martínez-sanchez P, Fernández-alonso M, Reina G, Trigo M, Echeverría M, Aguilera A, Navarro D, Bernal S, Lozano M, Fernández-cuenca F, Orduña A, Eiros J, Lejarazu ROD, Martínez-sapiña A, García-díaz A, Haque T. New findings in HCV genotype distribution in selected West European, Russian and Israeli regions. Journal of Clinical Virology 2016;81:82-9. [DOI: 10.1016/j.jcv.2016.05.010] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 7.3] [Reference Citation Analysis]
185 Papachristou E, Tsagkovits A, Zavitsanou A, Hatzakis A, Paraskevis D. HCV dispersal patterns among intravenous drug users (IDUs) in Athens metropolitan area. Infect Genet Evol 2016;45:415-9. [PMID: 27721034 DOI: 10.1016/j.meegid.2016.10.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
186 Kileng H, Bernfort L, Gutteberg T, Moen OS, Kristiansen MG, Paulssen EJ, Berg LK, Florholmen J, Goll R. Future complications of chronic hepatitis C in a low-risk area: projections from the hepatitis c study in Northern Norway. BMC Infect Dis 2017;17:624. [PMID: 28915795 DOI: 10.1186/s12879-017-2722-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
187 Hézode C, Hirschfield GM, Ghesquiere W, Sievert W, Rodriguez-Torres M, Shafran SD, Thuluvath PJ, Tatum HA, Waked I, Esmat G. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut. 2015;64:948-956. [PMID: 25080450 DOI: 10.1136/gutjnl-2014-307498] [Cited by in Crossref: 78] [Cited by in F6Publishing: 82] [Article Influence: 9.8] [Reference Citation Analysis]
188 Saludes V, Esteve M, Casas I, Ausina V, Martró E. Hepatitis C virus transmission during colonoscopy evidenced by phylogenetic analysis. Journal of Clinical Virology 2013;57:263-6. [DOI: 10.1016/j.jcv.2013.03.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
189 Höner zu Siederdissen C, Maasoumy B, Deterding K, Port K, Sollik L, Mix C, Kirschner J, Cornberg J, Manns MP, Wedemeyer H, Cornberg M. Eligibility and safety of the first interferon-free therapy against hepatitis C in a real-world setting. Liver Int 2015;35:1845-52. [DOI: 10.1111/liv.12774] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
190 Waffenschmidt S, Hermanns T, Gerber-Grote A, Mostardt S. No suitable precise or optimized epidemiologic search filters were available for bibliographic databases. J Clin Epidemiol 2017;82:112-8. [PMID: 27570049 DOI: 10.1016/j.jclinepi.2016.08.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
191 Buti M, Esteban R. Hepatitis C virus genotype 3: a genotype that is not ‘easy-to-treat’. Expert Rev Gastroenterol Hepatol. 2015;9:375-385. [PMID: 25222289 DOI: 10.1586/17474124.2015.960396] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
192 Klevens RM, Hu DJ, Jiles R, Holmberg SD. Evolving epidemiology of hepatitis C virus in the United States. Clin Infect Dis. 2012;55 Suppl 1:S3-S9. [PMID: 22715211 DOI: 10.1093/cid/cis393] [Cited by in Crossref: 133] [Cited by in F6Publishing: 126] [Article Influence: 13.3] [Reference Citation Analysis]
193 Cousien A, Obach D, Deuffic-Burban S, Mostafa A, Esmat G, Canva V, El Kassas M, El-Sayed M, Anwar WA, Fontanet A, Mohamed MK, Yazdanpanah Y. Is expert opinion reliable when estimating transition probabilities? The case of HCV-related cirrhosis in Egypt. BMC Med Res Methodol 2014;14:39. [PMID: 24635942 DOI: 10.1186/1471-2288-14-39] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
194 Saludes V, Folch C, Morales-Carmona A, Ferrer L, Fernàndez-López L, Muñoz R, Jiménez M, Loureiro E, Fernández-Dávila P, Bascuñana E, Casabona J, Martró E. Community-based screening of hepatitis C with a one-step RNA detection algorithm from dried-blood spots: Analysis of key populations in Barcelona, Spain. J Viral Hepat 2018;25:236-44. [PMID: 29053912 DOI: 10.1111/jvh.12809] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
195 Hadinedoushan H, Salmanroghani H, Amirbaigy MK, Akhondi-Meybodi M. Hepatitis C virus genotypes and association with viral load in yazd, central province of iran. Hepat Mon 2014;14:e11705. [PMID: 24693314 DOI: 10.5812/hepatmon.11705] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
196 Jadali Z. Autoimmune thyroid disorders in hepatitis C virus infection: Effect of interferon therapy. Indian J Endocrinol Metab 2013;17:69-75. [PMID: 23776855 DOI: 10.4103/2230-8210.107856] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
197 Rotily M, Vainchtock A, Jouaneton B, Wartelle-bladou C, Abergel A. How did chronic hepatitis C impact costs related to hospital health care in France in 2009? Clinics and Research in Hepatology and Gastroenterology 2013;37:365-72. [DOI: 10.1016/j.clinre.2012.11.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
198 Koutsoudakis G, Pérez-del-Pulgar S, González P, Crespo G, Navasa M, Forns X. A Gaussia luciferase cell-based system to assess the infection of cell culture- and serum-derived hepatitis C virus. PLoS One 2012;7:e53254. [PMID: 23300900 DOI: 10.1371/journal.pone.0053254] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
199 Flisiak R, Zarębska-Michaluk D. Perspectives of hepatitis C virus (HCV) elimination in Poland. Clin Exp Hepatol 2019;5:210-4. [PMID: 31598557 DOI: 10.5114/ceh.2019.87633] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
200 Falquetto TC, Endringer DC, Andrade TUD, Lenz D. Hepatitis C in prisoners and non-prisoners in Colatina, Espírito Santo, Brazil. Braz J Pharm Sci 2013;49:737-44. [DOI: 10.1590/s1984-82502013000400013] [Cited by in Crossref: 5] [Article Influence: 0.6] [Reference Citation Analysis]
201 Kosack CS, Nick S. Evaluation of two rapid screening assays for detecting hepatitis C antibodies in resource-constrained settings. Trop Med Int Health 2016;21:603-9. [DOI: 10.1111/tmi.12688] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
202 Lawitz E, Sullivan G, Rodriguez-Torres M, Bennett M, Poordad F, Kapoor M, Badri P, Campbell A, Rodrigues L Jr, Hu Y, Pilot-Matias T, Vilchez RA. Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection. J Infect. 2015;70:197-205. [PMID: 25246359 DOI: 10.1016/j.jinf.2014.09.008] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
203 Piselli P, Serraino D, Fusco M, Girardi E, Pirozzi A, Toffolutti F, Cimaglia C, Taborelli M; Collaborating Study Group. Hepatitis C virus infection and risk of liver-related and non-liver-related deaths: a population-based cohort study in Naples, southern Italy. BMC Infect Dis 2021;21:667. [PMID: 34238231 DOI: 10.1186/s12879-021-06336-9] [Reference Citation Analysis]
204 Negro F, Alberti A. The global health burden of hepatitis C virus infection: Editorial. Liver International 2011;31:1-3. [DOI: 10.1111/j.1478-3231.2011.02537.x] [Cited by in Crossref: 96] [Cited by in F6Publishing: 92] [Article Influence: 8.7] [Reference Citation Analysis]
205 Petruzziello A, Marigliano S, Loquercio G, Cacciapuoti C. Hepatitis C virus (HCV) genotypes distribution: an epidemiological up-date in Europe. Infect Agent Cancer. 2016;11:53. [PMID: 27752280 DOI: 10.1186/s13027-016-0099-0] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 6.8] [Reference Citation Analysis]
206 Bertisch B, Giudici F, Negro F, Moradpour D, Müllhaupt B, Moriggia A, Estill J, Keiser O; Swiss Hepatitis C Cohort Study. Characteristics of Foreign-Born Persons in the Swiss Hepatitis C Cohort Study: Implications for Screening Recommendations. PLoS One 2016;11:e0155464. [PMID: 27227332 DOI: 10.1371/journal.pone.0155464] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
207 Kauhl B, Heil J, Hoebe CJ, Schweikart J, Krafft T, Dukers-Muijrers NH. The Spatial Distribution of Hepatitis C Virus Infections and Associated Determinants--An Application of a Geographically Weighted Poisson Regression for Evidence-Based Screening Interventions in Hotspots. PLoS One 2015;10:e0135656. [PMID: 26352611 DOI: 10.1371/journal.pone.0135656] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 4.6] [Reference Citation Analysis]
208 Grassi E, Aghemo A. How to optimize HCV therapy in genotype 2 patients. Liver Int. 2013;33 Suppl 1:35-40. [PMID: 23286844 DOI: 10.1111/liv.12056] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
209 Gissel C, Götz G, Mahlich J, Repp H. Cost-effectiveness of Interferon-free therapy for Hepatitis C in Germany--an application of the efficiency frontier approach. BMC Infect Dis 2015;15:297. [PMID: 26223310 DOI: 10.1186/s12879-015-1048-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
210 Yehia BR, Schranz AJ, Umscheid CA, Lo Re V 3rd. The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis. PLoS One. 2014;9:e101554. [PMID: 24988388 DOI: 10.1371/journal.pone.0101554] [Cited by in Crossref: 259] [Cited by in F6Publishing: 254] [Article Influence: 32.4] [Reference Citation Analysis]
211 Tapper EB, Afdhal NH. Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3. J Viral Hepat. 2013;20:669-677. [PMID: 24010641 DOI: 10.1111/jvh.12168] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 6.4] [Reference Citation Analysis]
212 Papatheodoridis G, Thomas HC, Golna C, Bernardi M, Carballo M, Cornberg M, Dalekos G, Degertekin B, Dourakis S, Flisiak R, Goldberg D, Gore C, Goulis I, Hadziyannis S, Kalamitsis G, Kanavos P, Kautz A, Koskinas I, Leite BR, Malliori M, Manolakopoulos S, Matičič M, Papaevangelou V, Pirona A, Prati D, Raptopoulou-Gigi M, Reic T, Robaeys G, Schatz E, Souliotis K, Tountas Y, Wiktor S, Wilson D, Yfantopoulos J, Hatzakis A. Addressing barriers to the prevention, diagnosis and treatment of hepatitis B and C in the face of persisting fiscal constraints in Europe: report from a high level conference. J Viral Hepat 2016;23 Suppl 1:1-12. [PMID: 26809941 DOI: 10.1111/jvh.12493] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
213 Flisiak R, Jaroszewicz J, Flisiak I, Łapiński T. Update on alisporivir in treatment of viral hepatitis C. Expert Opin Investig Drugs 2012;21:375-82. [PMID: 22316207 DOI: 10.1517/13543784.2012.658641] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 3.7] [Reference Citation Analysis]
214 Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61:S45-S57. [PMID: 25086286 DOI: 10.1016/j.jhep.2014.07.027] [Cited by in Crossref: 1189] [Cited by in F6Publishing: 1085] [Article Influence: 148.6] [Reference Citation Analysis]
215 Müllhaupt B, Bruggmann P, Bihl F, Blach S, Lavanchy D, Razavi H, Semela D, Negro F. Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland. PLoS One 2015;10:e0125214. [PMID: 26107467 DOI: 10.1371/journal.pone.0125214] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
216 Lereau M, Fournier-wirth C, Mayen J, Farre C, Meyer A, Dugas V, Cantaloube J, Chaix C, Vasseur J, Morvan F. Development of Innovative and Versatile Polythiol Probes for Use on ELOSA or Electrochemical Biosensors: Application in Hepatitis C Virus Genotyping. Anal Chem 2013;85:9204-12. [DOI: 10.1021/ac401941x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
217 Mattlinger C, Thumfart JO, Heinen W, Michels H, Berres M, Vogt M, Jansky M. [Hepatitis C virus seroprevalence and dependency on country of origin of refugees in Rhineland-Palatinate, Germany in 2015]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2018;61:1472-80. [PMID: 30225596 DOI: 10.1007/s00103-018-2816-x] [Reference Citation Analysis]
218 Fadlalla FA, Mohamoud YA, Mumtaz GR, Abu-Raddad LJ. The epidemiology of hepatitis C virus in the Maghreb region: systematic review and meta-analyses. PLoS One. 2015;10:e0121873. [PMID: 25803848 DOI: 10.1371/journal.pone.0121873] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 5.4] [Reference Citation Analysis]
219 Chemaitelly H, Mahmud S, Rahmani AM, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Afghanistan: systematic review and meta-analysis. Int J Infect Dis 2015;40:54-63. [PMID: 26417880 DOI: 10.1016/j.ijid.2015.09.011] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
220 Roeder C, Jordan S, Schulze zur Wiesch J, Pfeiffer-Vornkahl H, Hueppe D, Mauss S, Zehnter E, Stoll S, Alshuth U, Lohse AW, Lueth S. Age-related differences in response to peginterferon alfa-2a/ribavirin in patients with chronic hepatitis C infection. World J Gastroenterol 2014; 20(31): 10984-10993 [PMID: 25152602 DOI: 10.3748/wjg.v20.i31.10984] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
221 Liberto MC, Marascio N, Zicca E, Matera G. Epidemiological features and specificities of HCV infection: a hospital-based cohort study in a university medical center of Calabria region. BMC Infect Dis. 2012;12 Suppl 2:S4. [PMID: 23173638 DOI: 10.1186/1471-2334-12-s2-s4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
222 Younossi Z, Brown A, Buti M, Fagiuoli S, Mauss S, Rosenberg W, Serfaty L, Srivastava A, Smith N, Stepanova M, Beckerman R. Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH-C) patients: an economic model from five European countries. J Viral Hepat 2016;23:217-26. [PMID: 26482680 DOI: 10.1111/jvh.12483] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 5.4] [Reference Citation Analysis]
223 Vermehren J, Schlosser B, Domke D, Elanjimattom S, Müller C, Hintereder G, Hensel-Wiegel K, Tauber R, Berger A, Haas N. High prevalence of anti-HCV antibodies in two metropolitan emergency departments in Germany: a prospective screening analysis of 28,809 patients. PLoS One. 2012;7:e41206. [PMID: 22848445 DOI: 10.1371/journal.pone.0041206] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
224 de Carvalho JR, Villela-Nogueira CA, Perez RM, Portugal FB, Flor LS, Campos MR, Schramm JMA. Burden of Chronic Viral Hepatitis and Liver Cirrhosis in Brazil - the Brazilian Global Burden of Disease Study. Ann Hepatol. 2017;16:893-900. [PMID: 29055917 DOI: 10.5604/01.3001.0010.5280] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
225 Cornberg M, Höner zu Siederdissen C, Maasoumy B, Manns MP. [New direct-acting antiviral agents for the treatment of chronic hepatitis C in 2014]. Internist (Berl) 2014;55:390-400. [PMID: 24652513 DOI: 10.1007/s00108-013-3416-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
226 Dalgard O, Mauss S. No strategy to meet the HCV epidemic. BMC Infect Dis. 2014;14 Suppl 6:S2. [PMID: 25253032 DOI: 10.1186/1471-2334-14-s6-s2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
227 Rouabhia S, Sadelaoud M, Chaabna-Mokrane K, Toumi W, Abenavoli L. Hepatitis C virus genotypes in north eastern Algeria: A retrospective study. World J Hepatol 2013; 5(7): 393-397 [PMID: 23898373 DOI: 10.4254/wjh.v5.i7.393] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
228 Vassilopoulos D, Calabrese LH. Management of rheumatic disease with comorbid HBV or HCV infection. Nat Rev Rheumatol 2012;8:348-57. [DOI: 10.1038/nrrheum.2012.63] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 4.4] [Reference Citation Analysis]
229 Czerwinski M, Grabarczyk P, Stepien M, Kubicka-Russel D, Tkaczuk K, Brojer E, Rosinska M. What weighs more-low compliance with self-deferral or minor medical procedures? Explaining the high rate of hepatitis C virus window-period donations in Poland. Transfusion 2017;57:1998-2006. [PMID: 28555775 DOI: 10.1111/trf.14163] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
230 Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet. 2015;385:1124-1135. [PMID: 25687730 DOI: 10.1016/s0140-6736(14)62401-6] [Cited by in Crossref: 335] [Cited by in F6Publishing: 143] [Article Influence: 47.9] [Reference Citation Analysis]
231 Selvarajah S, Busch MP. Transfusion transmission of HCV, a long but successful road map to safety. Antivir Ther 2012;17:1423-9. [PMID: 23322562 DOI: 10.3851/IMP2459] [Cited by in Crossref: 22] [Cited by in F6Publishing: 4] [Article Influence: 2.2] [Reference Citation Analysis]
232 Walewska-Zielecka B, Religioni U, Juszczyk G, Wawrzyniak ZM, Czerw A, Soszyński P, Fronczak A. Anti-hepatitis C virus seroprevalence in the working age population in Poland, 2004 to 2014. Euro Surveill 2017;22:30441. [PMID: 28106526 DOI: 10.2807/1560-7917.ES.2017.22.2.30441] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
233 Heidrich B, Steinmann E, Plumeier I, Kirschner J, Sollik L, Ziegert S, Engelmann M, Lehmann P, Manns MP, Pieper DH, Wedemeyer H. Frequent detection of HCV RNA and HCVcoreAg in stool of patients with chronic hepatitis C. Journal of Clinical Virology 2016;80:1-7. [DOI: 10.1016/j.jcv.2016.04.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
234 Mogalian E, German P, Kearney BP, Yang CY, Brainard D, Link J, McNally J, Han L, Ling J, Mathias A. Preclinical Pharmacokinetics and First-in-Human Pharmacokinetics, Safety, and Tolerability of Velpatasvir, a Pangenotypic Hepatitis C Virus NS5A Inhibitor, in Healthy Subjects. Antimicrob Agents Chemother 2017;61:e02084-16. [PMID: 28193657 DOI: 10.1128/AAC.02084-16] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 3.8] [Reference Citation Analysis]
235 Signorovitch JE, Betts KA, Song Y, Sorg RA, Li J, Behl AS, Kalsekar A. Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection. J Comp Eff Res. 2015;4:593-605. [PMID: 26159375 DOI: 10.2217/cer.15.33] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
236 Marshall AD, Pawlotsky J, Lazarus JV, Aghemo A, Dore GJ, Grebely J. The removal of DAA restrictions in Europe – One step closer to eliminating HCV as a major public health threat. Journal of Hepatology 2018;69:1188-96. [DOI: 10.1016/j.jhep.2018.06.016] [Cited by in Crossref: 53] [Cited by in F6Publishing: 53] [Article Influence: 13.3] [Reference Citation Analysis]
237 Sacchini D, Craxì L, Refolo P, Minacori R, Cicchetti A, Gasbarrini A, Cammà C, Spagnolo AG; WEF Study Group. Ethical assessment of hepatitis C virus treatment: The lesson from first generation protease inhibitors. Dig Liver Dis 2015;47:351-5. [PMID: 25534233 DOI: 10.1016/j.dld.2014.11.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
238 Grzeszczuk A, Wandalowicz AD, Jaroszewicz J, Flisiak R. Prevalence and Risk Factors of HCV/HIV Co-Infection and HCV Genotype Distribution in North-Eastern Poland. Hepat Mon 2015;15:e27740. [PMID: 26300929 DOI: 10.5812/hepatmon.27740v2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
239 Andriulli A, Morisco F, Ippolito AM, Di Marco V, Valvano MR, Angelico M, Fattovich G, Granata R, Smedile A, Milella M, Felder M, Gaeta GB, Gatti P, Fasano M, Mazzella G, Santantonio T. HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcome. Hepatol Int 2015;9:52-7. [PMID: 25788379 DOI: 10.1007/s12072-014-9556-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
240 Papatheodoridis G, Sypsa V, Kantzanou M, Nikolakopoulos I, Hatzakis A. Estimating the treatment cascade of chronic hepatitis B and C in Greece using a telephone survey. J Viral Hepat. 2015;22:409-415. [PMID: 25209157 DOI: 10.1111/jvh.12314] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
241 Maasoumy B, Bremer B, Raupach R, Lehmann P, Manns MP, Cornberg M, Wedemeyer H. How to interpret borderline HCV antibody test results: a comparative study investigating four different anti-HCV assays. Viral Immunol 2014;27:7-13. [PMID: 24494968 DOI: 10.1089/vim.2013.0064] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
242 Buti M, Homs M. Nuevos agentes para el tratamiento de la hepatitis C. Enfermedades Infecciosas y Microbiología Clínica 2012;30:147-50. [DOI: 10.1016/j.eimc.2011.09.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
243 Lavanchy D, Lavanchy D. Hepatitis C Virus Infection Trends in Italy. Hepat Mon 2012;12:46-7. [DOI: 10.5812/hepatmon.4403] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
244 Bokharaei-Salim F, Keyvani H, Monavari SH, Alavian SM, Fakhim S, Nasseri S. Distribution of hepatitis C virus genotypes among azerbaijani patients in capital city of iran-tehran. Hepat Mon 2013;13:e13699. [PMID: 24282427 DOI: 10.5812/hepatmon.13699] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
245 El-Ghitany EM, Farghaly AG. Geospatial epidemiology of hepatitis C infection in Egypt 2017 by governorate. Heliyon 2019;5:e02249. [PMID: 31463388 DOI: 10.1016/j.heliyon.2019.e02249] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
246 Macías J, López-Cortés LF, Téllez F, Recio E, Ojeda-Burgos G, Ríos MJ, Rivero-Juárez A, Delgado M, Rivas-Jeremías, Pineda JA. Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection. PLoS One 2015;10:e0143492. [PMID: 26640956 DOI: 10.1371/journal.pone.0143492] [Reference Citation Analysis]
247 Abenavoli L, Rouabhia S. Type 2 diabetes mellitus in chronic hepatitis C virus infection: risk factor or consequence? Expert Rev Gastroenterol Hepatol. 2013;7:295-297. [PMID: 23639086 DOI: 10.1586/egh.13.13] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
248 Pozzetto B, Memmi M, Garraud O, Roblin X, Berthelot P. Health care-associated hepatitis C virus infection. World J Gastroenterol 2014; 20(46): 17265-17278 [PMID: 25516637 DOI: 10.3748/wjg.v20.i46.17265] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
249 Drositis I, Bertsias A, Lionis C, Kouroumalis E. Epidemiology and molecular analysis of hepatitis A, B and C in a semi-urban and rural area of Crete. Eur J Intern Med. 2013;24:839-845. [PMID: 23988264 DOI: 10.1016/j.ejim.2013.08.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
250 Chayama K, Takahashi S, Toyota J, Karino Y, Ikeda K, Ishikawa H, Watanabe H, McPhee F, Hughes E, Kumada H. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology. 2012;55:742-748. [PMID: 21987462 DOI: 10.1002/hep.24724] [Cited by in Crossref: 270] [Cited by in F6Publishing: 251] [Article Influence: 27.0] [Reference Citation Analysis]
251 Bernieh B. Viral hepatitis in hemodialysis: An update. J Transl Int Med. 2015;3:93-105. [PMID: 27847896 DOI: 10.1515/jtim-2015-0018] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
252 Morrison MH, Keane C, Quinn LM, Kelly A, O'Farrelly C, Bergin C, Gardiner CM. IFNL cytokines do not modulate human or murine NK cell functions. Hum Immunol 2014;75:996-1000. [PMID: 24994459 DOI: 10.1016/j.humimm.2014.06.016] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
253 Mohamoud YA, Riome S, Abu-Raddad LJ. Epidemiology of hepatitis C virus in the Arabian Gulf countries: Systematic review and meta-analysis of prevalence. Int J Infect Dis. 2016;46:116-125. [PMID: 26996460 DOI: 10.1016/j.ijid.2016.03.012] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 5.8] [Reference Citation Analysis]
254 Zehender G, Sorrentino C, Lai A, Ebranati E, Gabanelli E, Lo Presti A, Vujoševic D, Lauševic D, Terzić D, Shkjezi R, Bino S, Vratnica Z, Mugosa B, Galli M, Ciccozzi M. Reconstruction of the evolutionary dynamics of hepatitis C virus subtypes in Montenegro and the Balkan region. Infect Genet Evol 2013;17:223-30. [PMID: 23603418 DOI: 10.1016/j.meegid.2013.04.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
255 Geenen JW, Boersma C, Klungel OH, Hövels AM. Accuracy of budget impact estimations and impact on patient access: a hepatitis C case study. Eur J Health Econ 2019;20:857-67. [PMID: 30953216 DOI: 10.1007/s10198-019-01048-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
256 Chaabna K, Mohamoud YA, Chemaitelly H, Mumtaz GR, Abu-raddad LJ. Protocol for a systematic review and meta-analysis of hepatitis C virus (HCV) prevalence and incidence in the Horn of Africa sub-region of the Middle East and North Africa. Syst Rev 2014;3. [DOI: 10.1186/2046-4053-3-146] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
257 Cousien A, Tran VC, Deuffic-Burban S, Jauffret-Roustide M, Dhersin JS, Yazdanpanah Y. Hepatitis C treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs. Hepatology 2016;63:1090-101. [PMID: 26390137 DOI: 10.1002/hep.28227] [Cited by in Crossref: 65] [Cited by in F6Publishing: 57] [Article Influence: 9.3] [Reference Citation Analysis]
258 Hellard ME, Doyle JS. Interferon-free hepatitis C treatment: one pill to fit all? Lancet 2014;383:491-2. [PMID: 24209978 DOI: 10.1016/S0140-6736(13)62151-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]